REG-PanGenomic Health Inc: PanGenomic Health Announces Q3 Financial Results

Pangenomic HealthAnnouncement

30/11/2023 07:15

30 November 2023

 

PanGenomic Health Inc.

("PanGenomic" or the "Company")

 

PanGenomic Health Announces Q3 Financial Results

 

Vancouver, British Columbia, Canada, 30 November 2023 - PanGenomic Health Inc.
("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to
announce that it has filed its unaudited financial results for the third
quarterly period ending 30 September 2023 of the Company's 2023 fiscal year.
The full set of Consolidated Financial Statements and Management Discussion
and Analysis can be viewed by visiting the Company's website at
www.pangenomic.com or its profile page on SEDAR at www.sedar.com.

 

 

The Directors of PanGenomic take responsibility for this announcement.

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under Article 17 of
MAR.

 

 

For more information, please contact:

 

Jerry Lai, Investor Relations    Maryam Marissen, President & CEO

PanGenomic Health Inc.    PanGenomic Health Inc.

778 743 4642      778 743 4642

ir@pangenomic.com     info@pangenomic.com

 

Novum Securities Limited, AQSE Corporate Advisor

David Coffman / George Duxberry

Tel: +44 (0)207 399 9400

 

 

About PanGenomic Health

 

PanGenomic Health is a precision health company that has developed a self-care
digital platform to deliver personalised, evidence-based information about
natural treatments. The Company's initial focus is to support mental health.
Registered as a British Columbia benefit company, PanGenomic Health's mission
is to promote and improve the health and wellness of people and society by
providing a technology platform that identifies plant-based solutions tailored
to the health profile of each individual.

 

 

 

 



Copyright (c) 2023 PR Newswire Association,LLC. All Rights Reserved